\BOOKMARK [0][-]{section*.2}{Sum\341rio}{}% 1
\BOOKMARK [0][-]{section*.3}{Lista de Figuras}{}% 2
\BOOKMARK [0][-]{section*.4}{Lista de Tabelas}{}% 3
\BOOKMARK [0][-]{chapter.1}{Introdu\347\343o}{}% 4
\BOOKMARK [1][-]{section.1.1}{Tumores cerebrais na inf\342ncia e adolesc\352ncia}{chapter.1}% 5
\BOOKMARK [1][-]{section.1.2}{Por qu\352 criar um comp\352ndio de protocolos de quimioterapia?}{chapter.1}% 6
\BOOKMARK [0][-]{chapter.2}{O tratamento de tumores cerebrais em crian\347as}{}% 7
\BOOKMARK [1][-]{section.2.1}{Gliomas de baixo grau}{chapter.2}% 8
\BOOKMARK [2][-]{subsection.2.1.1}{Avalia\347\343o cr\355tica de ensaios cl\355nicos}{section.2.1}% 9
\BOOKMARK [2][-]{subsection.2.1.2}{O panorama molecular dos gliomas de baixo grau}{section.2.1}% 10
\BOOKMARK [1][-]{section.2.2}{Tumores embrion\341rios e pineoblastoma}{chapter.2}% 11
\BOOKMARK [0][-]{section*.10}{Refer\352ncias Bibliogr\341ficas}{}% 12
\BOOKMARK [0][-]{chapter.3}{Esquemas de tratamento}{}% 13
\BOOKMARK [1][-]{section.3.1}{Introdu\347\343o}{chapter.3}% 14
\BOOKMARK [1][-]{section.3.2}{O que s\343o estes protocolos}{chapter.3}% 15
\BOOKMARK [1][-]{section.3.3}{Como utilizar estes protocolos}{chapter.3}% 16
\BOOKMARK [1][-]{section.3.4}{Formato e contribui\347\365es}{chapter.3}% 17
\BOOKMARK [0][-]{appendix.A}{Protocolos principais}{}% 18
\BOOKMARK [1][-]{section.A.1}{GLIOMA DE BAIXO GRAU \205 Adaptado do ensaio COG-A9952}{appendix.A}% 19
\BOOKMARK [2][-]{subsection.A.1.1}{Indu\347\343o: 10 semanas}{section.A.1}% 20
\BOOKMARK [2][-]{subsection.A.1.2}{Manuten\347\343o: 48 semanas \(08 blocos de 6 semanas\)}{section.A.1}% 21
\BOOKMARK [2][-]{subsection.A.1.3}{Modifica\347\365es de dose:}{section.A.1}% 22
\BOOKMARK [1][-]{section.A.2}{GLIOMA DE BAIXO GRAU: TRATAMENTO ALTERNATIVO DE PRIMEIRA LINHA, SEGUNDA LINHA NA CONTRA-INDICA\307\303O AO USO DA CARBOPLATINA OU RECORR\312NCIA AP\323S TRATAMENTO}{appendix.A}% 23
\BOOKMARK [2][-]{subsection.A.2.1}{Quimioterapia adjuvante: 52 semanas ou 1 ano}{section.A.2}% 24
\BOOKMARK [2][-]{subsection.A.2.2}{Modifica\347\365es de dose:}{section.A.2}% 25
\BOOKMARK [1][-]{section.A.3}{MEDULOBLASTOMA - RISCO PADR\303O \205 Adaptado dos ensaios CCG-9961 e ACNS0331}{appendix.A}% 26
\BOOKMARK [2][-]{subsection.A.3.1}{Radioquimioterapia: 7 semanas \(43 dias\)}{section.A.3}% 27
\BOOKMARK [2][-]{subsection.A.3.2}{Manuten\347\343o: 04 ciclos A e 04 ciclos B}{section.A.3}% 28
\BOOKMARK [2][-]{subsection.A.3.3}{Modifica\347\365es de dose:}{section.A.3}% 29
\BOOKMARK [1][-]{section.A.4}{TUMORES MALIGNOS DO SNC EM MENORES DE 3 ANOS \205 Adaptado do ensaio CCG 9921}{appendix.A}% 30
\BOOKMARK [2][-]{subsection.A.4.1}{Indu\347\343o: 5 ciclos \(VCEC\)}{section.A.4}% 31
\BOOKMARK [2][-]{subsection.A.4.2}{Manuten\347\343o: 08 ciclos}{section.A.4}% 32
\BOOKMARK [2][-]{subsection.A.4.3}{Modifica\347\365es de dose:}{section.A.4}% 33
\BOOKMARK [1][-]{section.A.5}{EPENDIMOMA \205 Adaptado dos ensaios do COG e SIOP e de dados combinados da literatura}{appendix.A}% 34
\BOOKMARK [0][-]{appendix.B}{Protocolos off-label \(n\343o padronizados\)}{}% 35
\BOOKMARK [1][-]{section.B.1}{PNET - ALTO RISCO \205 Adaptado dos ensaios COG-A99701 e ACNS0332 - protocolo off-label}{appendix.B}% 36
\BOOKMARK [2][-]{subsection.B.1.1}{Radioquimioterapia: 7 semanas \(43 dias\)}{section.B.1}% 37
\BOOKMARK [2][-]{subsection.B.1.2}{Manuten\347\343o: 06 ciclos}{section.B.1}% 38
\BOOKMARK [2][-]{subsection.B.1.3}{Modifica\347\365es de dose:}{section.B.1}% 39
\BOOKMARK [1][-]{section.B.2}{GLIOMA DE ALTO GRAU E DIPG \205 Adaptado do ensaio ACNS0423 - protocolo off-label}{appendix.B}% 40
\BOOKMARK [2][-]{subsection.B.2.1}{Indu\347\343o: 6 semanas \(radioquimioterapia\)}{section.B.2}% 41
\BOOKMARK [2][-]{subsection.B.2.2}{Manuten\347\343o: 06 ciclos}{section.B.2}% 42
\BOOKMARK [2][-]{subsection.B.2.3}{Modifica\347\365es de dose:}{section.B.2}% 43
\BOOKMARK [1][-]{section.B.3}{GLIOMA DE ALTO GRAU E DIPG \205 Adaptado do ensaio HIT-GBM-D - protocolo off-label}{appendix.B}% 44
\BOOKMARK [2][-]{subsection.B.3.1}{Indu\347\343o: 6 semanas \(radioquimioterapia\)}{section.B.3}% 45
\BOOKMARK [2][-]{subsection.B.3.2}{Manuten\347\343o: 08 ciclos}{section.B.3}% 46
\BOOKMARK [2][-]{subsection.B.3.3}{Modifica\347\365es de dose:}{section.B.3}% 47
\BOOKMARK [0][-]{appendix.C}{Quimioterapia de resgate \(doen\347a recorrente/progressiva\)}{}% 48
\BOOKMARK [1][-]{section.C.1}{TUMORES PEDI\301TRICOS DO SISTEMA NERVOSO CENTRAL RECORRENTES \(protocolo off-label\)}{appendix.C}% 49
\BOOKMARK [2][-]{subsection.C.1.1}{Quimioterapia: 10 ciclos}{section.C.1}% 50
\BOOKMARK [2][-]{subsection.C.1.2}{Modifica\347\365es de dose:}{section.C.1}% 51
\BOOKMARK [1][-]{section.C.2}{IFOSFAMIDA/ETOPOSIDO - protocolo off-label}{appendix.C}% 52
\BOOKMARK [2][-]{subsection.C.2.1}{Resgate: 03 ciclos - repetir enquanto n\343o houver progress\343o}{section.C.2}% 53
\BOOKMARK [2][-]{subsection.C.2.2}{Modifica\347\365es de dose:}{section.C.2}% 54
\BOOKMARK [1][-]{section.C.3}{IFOSFAMIDA, CARBOPLATINA E ETOPOSIDO \(ICE\) - protocolo off-label}{appendix.C}% 55
\BOOKMARK [2][-]{subsection.C.3.1}{Resgate: 02 ciclos - repetir enquanto n\343o houver progress\343o}{section.C.3}% 56
\BOOKMARK [2][-]{subsection.C.3.2}{Modifica\347\365es de dose:}{section.C.3}% 57
\BOOKMARK [0][-]{appendix.D}{Quimioterapia neoadjuvante}{}% 58
\BOOKMARK [1][-]{section.D.1}{VIMBLASTINA METRON\324MICA NEOADJUVANTE - protocolo off-label}{appendix.D}% 59
\BOOKMARK [2][-]{subsection.D.1.1}{Esquema: 6 semanas}{section.D.1}% 60
\BOOKMARK [2][-]{subsection.D.1.2}{Modifica\347\365es de dose:}{section.D.1}% 61
\BOOKMARK [1][-]{section.D.2}{IFOSFAMIDA, CARBOPLATINA E ETOPOSIDO \(ICE\) NEOADJUVANTE PARA TUMORES DE PLEXO COR\323IDE - protocolo off-label}{appendix.D}% 62
\BOOKMARK [2][-]{subsection.D.2.1}{Dois ciclos - repetir uma vez se necess\341rio e n\343o houver progress\343o}{section.D.2}% 63
\BOOKMARK [2][-]{subsection.D.2.2}{Modifica\347\365es de dose:}{section.D.2}% 64
\BOOKMARK [0][-]{appendix.E}{Quimioterapia metron\364mica}{}% 65
\BOOKMARK [1][-]{section.E.1}{VIMBLASTINA SEMANAL METRON\324MICA - protocolo off-label}{appendix.E}% 66
\BOOKMARK [2][-]{subsection.E.1.1}{Esquema 1: 6 semanas - usar esquema 1 ou 2, n\343o ambos}{section.E.1}% 67
\BOOKMARK [2][-]{subsection.E.1.2}{Esquema 2: 6 semanas - usar esquema 1 ou 2, n\343o ambos}{section.E.1}% 68
\BOOKMARK [2][-]{subsection.E.1.3}{Modifica\347\365es de dose:}{section.E.1}% 69
\BOOKMARK [0][-]{appendix.F}{Protocolos depreciados \(substitu\355dos por atualiza\347\365es\)}{}% 70
\BOOKMARK [1][-]{section.F.1}{GLIOMA DE ALTO GRAU E DIPG \205 Adaptado do ensaio ACNS0126}{appendix.F}% 71
\BOOKMARK [2][-]{subsection.F.1.1}{Indu\347\343o: 6 semanas \(radioquimioterapia\)}{section.F.1}% 72
\BOOKMARK [2][-]{subsection.F.1.2}{Manuten\347\343o: 10 ciclos}{section.F.1}% 73
\BOOKMARK [2][-]{subsection.F.1.3}{Modifica\347\365es de dose:}{section.F.1}% 74
\BOOKMARK [1][-]{section.F.2}{EPENDIMOMA N\303O METAST\301TICO \205 Adaptado dos ensaios ACNS0121 e ACNS0831}{appendix.F}% 75
\BOOKMARK [2][-]{subsection.F.2.1}{Indu\347\343o: 2 ciclos \(pr\351-radioterapia\)}{section.F.2}% 76
\BOOKMARK [2][-]{subsection.F.2.2}{Manuten\347\343o: 04 ciclos \(VCEC\)}{section.F.2}% 77
\BOOKMARK [2][-]{subsection.F.2.3}{Modifica\347\365es de dose:}{section.F.2}% 78
\BOOKMARK [0][-]{appendix.G}{Protocolos experimentais \(estudos cl\355nicos\)}{}% 79
\BOOKMARK [1][-]{section.G.1}{VALQUIRIA \(VALPROATO, QUIMIOTERAPIA E RADIOTERAPIA - protocolo experimental cancelado}{appendix.G}% 80
\BOOKMARK [2][-]{subsection.G.1.1}{Resumo do tratamento:}{section.G.1}% 81
\BOOKMARK [2][-]{subsection.G.1.2}{Indu\347\343o: 6 semanas \(radioquimioterapia\)}{section.G.1}% 82
\BOOKMARK [2][-]{subsection.G.1.3}{Manuten\347\343o: 08 ciclos}{section.G.1}% 83
\BOOKMARK [2][-]{subsection.G.1.4}{Modifica\347\365es de dose:}{section.G.1}% 84
